Lead specialists from Novartis are set to discuss challenges and lessons learnt from recent developments of antibody drug conjugates at the 5th ADC Summit in London on 23 - 24 May 2016. The two-day event provides a comprehensive analysis of the various approaches with the next generation ADCs led by industry experts including Roche, Takeda, Pfizer, AstraZeneca, Bayer and more. Visit the website for more information.
Jens Lohrmann, Senior Global Program Manager for Translational Clinical Oncology will be presenting about the challenges and lessons learnt in ADC CMC development and outsourcing. He will cover the following topics:
- Buy vs make: considerations and critical success factors
- Scale-up and site transfer of a conjugation process with impact on key product quality attributes
- Analytical transfers: considerations and lessons from a challenging assay transfers.
Carl Uli Bialucha, Senior Investigator I for Oncology Biotherapeutics, will present about "Targeting Cadherin-6 with a novel ADC for the treatment of ovarian and renal cancers". His session will discuss
- ADC lead selection covering optimal choice of antibody and linker/payload
- PK/PD studies to evaluate MoA and projected efficacious dose
- Population-scale in vivo assessment in ovarian cancer PTX clinical trial.
Other key presentations include:
- ADCETRIS developed to treat Hodgkin Lymphoma - Ashish Gautam, Global Medical Lead - ADCETRIS, Takeda
- Predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies - Ben-Fillippo Krippendeorff, Principal Scientist, Roche
- Impact of drug loading on ADC target binding and cytotoxicity - Debbie Meyer, Senior Principal Scientist, Pfizer
- The design, synthesis and scale-up of an ADC tubulysin - Jeremy Parker, Principal Scientist, Pharmaceutical Development, AstraZeneca and many more.
To download a complimentary agenda and to view the full speaker lineup and their topics, please visit http://www.adcsummit.com/mednewstoday.
In addition to the conference, the event will feature two exclusive half-day post-conference workshops held on the 25 May 2016:
- ADC payloads: Availability and mechanisms of action - Hosted by Femtogenix and King's Cross London
- Developments in high potency API manufacturing - Hosted by SKAN AG
An Early Bird discount of £400 applies to all bookings made by 29 February. For more information or to register visit the event website at http://www.adcsummit.com/mednewstoday.
For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: firstname.lastname@example.org.
For group/delegate bookings contact Fateja Begum on +44 (0) 20 7827 6184 or email email@example.com.
For media enquiries contact Honey de Gracia on +44 (0) 20 7827 6102 or email firstname.lastname@example.org.